Cochrane HIV/AIDS Group:

Reviews, Protocols and Registered Titles: Cochrane Library Issue 3, 2008 (July 2008)

Return to Cochrane HIV/AIDS Group main page

R = Finished review

P = Protocol stage (published)

T = Registered title

• Reviews of Behavioral, Social and Policy Prevention

• Reviews of Biomedical Prevention

• Reviews of Therapeutics, Prognostics and Diagnostics

• Reviews of Health Services and Care

• Registered Titles

Reviews of Behavioral, Social and Policy Prevention

é Sex-related HIV risk reduction

¨ R Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men

é Condom use

¨ P Structural and community-level interventions for increasing condom use to prevent HIV and other sexually transmitted infections.

é Drug-related HIV risk reduction

Drug-related behavior change

¨ P Psychosocial interventions for the reduction of injection and sexual risk behaviour for preventing HIV in drug users

é Interventions targeting specific populations

¨ P Behavioral interventions for decreasing HIV infection in racial and ethnic minorities in high-income economies

¨ P Behavioral interventions for reducing HIV infection in employees in occupational settings

¨ P Behavioral interventions to reduce the transmission of HIV infection among commercial sex workers and their clients in developed countries

¨ P Behavioral interventions to reduce the transmission of HIV infection among commercial sex workers and their clients in developing countries

¨ P Harm reduction interventions to prevent HIV/AIDS transmission in involuntary detainees

¨ P Interventions for improving the psychosocial wellbeing of children affected by HIV/AIDS.

¨ P Peer-based interventions for reducing morbidity and mortality in HIV-infected women

é Specific types of interventions

¨ R Abstinence-only programs for HIV infection prevention in high-income countries

¨ R Abstinence-plus programs for HIV infection prevention in high-income countries

¨ P Counseling and testing for preventing HIV infection

¨ R Home-based HIV voluntary counseling and testing in developing countries

¨ P Interventions for reduction of stigma in people with HIV/AIDS

¨ R Mass media interventions for promoting HIV testing

¨ P Rapid HIV tests and counseling for pregnant women for preventing mother-to-child HIV transmission

¨ P Routine vs. voluntary HIV testing for increasing HIV testing rates

¨ P School-based interventions to postpone sexual intercourse and promote condom use among adolescents

Reviews of Biomedical Prevention

é Post-exposure prophylaxis

¨ R Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure

¨ P Effectiveness and safety of HIV post-exposure prophylaxis after sexual, injecting-drug-use or other non-occupational exposure.

é Pre-exposure prophylaxis

¨ P Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high risk individuals.

é Prevention of perinatal transmission

¨ R Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection

¨ R Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1

¨ P Interventions for preventing postnatal mother-to-child transmission of HIV

¨ R Interventions for reducing the risk of mother-to-child transmission of HIV infection

¨ R Vaginal disinfection for preventing mother-to-child transmission of HIV infection

¨ R Vitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infection

é Condom efficacy

¨ R Condom effectiveness in reducing heterosexual HIV transmission

¨ P Female condom for preventing HIV and sexually transmitted infections

é STI treatment

¨ R Population-based interventions for reducing sexually transmitted infections, including HIV infection

é Microbicides

¨ R Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men

é Circumcision

¨ R Male circumcision for prevention of heterosexual acquisition of HIV in men

é Vaccines

é Safety of blood products

é Syringe and needle use

Reviews of Therapeutics, Prognostics and Diagnostics

é Antiretrovirals, including protease inhibitors

Combination therapy

¨ P A combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDS

¨ R Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy

¨ P Efavirenz versus nevirapine as a non-nucleoside reverse transcriptase inhibitor in initial combination antiretroviral therapy for HIV infection

¨ P Effectiveness and safety of first-line fixed-dose TNF + EMC + EFZ for patients with HIV

¨ P Ritonavir-boosted protease inhibitor-containing regimens versus non-boosted protease-inhibitor-containing regimens for reducing morbidity and mortality in people with HIV/AIDS

¨ R Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.

¨ R Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection

Single drugs

¨ R Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults

¨ R Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults

Structured treatment interruptions

¨ R Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults

¨ R Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults

HIV+ children

¨ P Antiretroviral therapy for HIV-infected children

é Prophylaxis and treatment of opportunistic infections (OIs)

Prophylaxis

¨ R Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection

¨ R Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV

¨ R Cotrimoxazole for prophylaxis or treatment of opportunistic infections of HIV/AIDS in patients with previous history of hypersensitivity to cotrimoxazole

¨ R Cotrimoxazole prophylaxis for opportunistic infections in adults with HIV

¨ R Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection

¨ P Interventions for the prevention of mycobacterium avium complex in adults and children with HIV

¨ R Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings)

¨ P The impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV-infected children

TB

¨ P Duration of therapy for tuberculosis in patients infected with Human Immunodeficiency Virus

¨ R Treatment of latent tuberculosis infection in HIV infected persons

Oropharyngeal infections

¨ R Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children

Cryptosporidiosis

¨ R Prevention and treatment of cryptosporidiosis in immunocompromised patients

é Treatment of Malignancies

¨ R Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals

¨ R Interventions for treating AIDS-associated Hodgkin´s lymphoma in treatment-naive adults

¨ P Interventions for treating AIDS-associated Non-Hodgkin´s Lymphoma (NHL) in treatment-naive adults with AIDS

¨ R Treatment of Kaposis sarcoma in HIV-1 infected individuals with emphasis on resource poor settings

é Immunizations

¨ P Influenza vaccine for people with HIV/AIDS

¨ P Measles/MMR vaccine for infants born to HIV-positive mothers

¨ P Pneumococcal vaccine for prevention of Streptococcus pneumoniae infection in HIV infected persons.

é Prognostics Markers

¨ P Antiretroviral resistance testing in treatment-naive HIV-infected adults

¨ P Genotypic antiretroviral resistance testing at viral failure in people with HIV

¨ P Therapeutic drug monitoring of antiretrovirals for people with HIV

é Diagnostics Assays

é Complementary Medicine

¨ R Herbal medicines for treating HIV infection and AIDS

¨ P The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS

é Treatment of other conditions

¨ R Adjunctive therapies for AIDS dementia complex

¨ P The effects of antiviral therapy of genital herpes in HIV-infected individuals

¨ R Treatment for anemia in people with AIDS

¨ R Treatment of helminth co-infection in HIV-1 infected individuals in resource-limited settings.

Reviews of Health Services and Care

é Health care characteristics

¨ P Interventions for Educating Traditional Healers about STD and HIV Medicine

¨ P Provider training and experience for people living with HIV/AIDS

¨ R Setting and organization of care for persons living with HIV/AIDS

é Quality of life

¨ R Aerobic exercise interventions for adults living with HIV/AIDS

¨ R Anabolic steroids for the treatment of weight loss in HIV-infected individuals

¨ P Cognitive behavioural therapy (CBT) for adults with HIV

¨ P Family support in reducing morbidity and mortality in HIV-infected persons

¨ P Home-based care for reducing morbidity and mortality in people infected with HIV/AIDS

¨ P Iron supplementation for reducing morbidity and mortality in children with HIV

¨ R Micronutrient supplementation in children and adults with HIV infection

¨ R Nutritional interventions for reducing morbidity and mortality in people with HIV

¨ R Progressive resistive exercise interventions for adults living with HIV/AIDS

é Treatment adherence

¨ R Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS

¨ P Substitution of nurses for doctors in managing HIV/AIDS antiretroviral therapy

REGISTERED TITLES

¨ T Abstinence-promotion interventions for HIV prevention in developing countries

¨ T Antidepressants to treat depression in people with HIV/AIDS

¨ T Antiviral agents for treating CMV infection of the nervous system in people with HIV

¨ T Interventions to modify sexual risk behaviours for preventing HIV in homeless youth

¨ T Behavioral interventions for modifying sexual risk behaviors in women with HIV/AIDS

¨ T Behavioural interventions for preventing HIV in refugee camps

¨ T Interventions for decreasing stigma in people with HIV/AIDS

¨ T Interventions for preventing HIV-related sexual violence

¨ T Low-dose stavudine versus high-dose stavudine for treating people with HIV

¨ T Male circumcision for prevention of homosexual acquisition of HIV

¨ T Massage therapy for people with HIV

¨ T Motivational interviewing for reducing morbidity and mortality in people with HIV

¨ T Timing for initiation of antiretroviral therapy in asymptomatic, treatment-naive adults with HIV

¨ T Topical microbicides for preventing HIV infection

¨ T Topical treatments for HIV-induced oral ulcerations

¨ T Treatment for herpes zoster ophthalmicus in people with HIV infection

¨ T Treatment for leiomyosarcoma and leiomyoma in children with HIV infection

¨ T Vaccines for prevention of HIV infection